|
|
|
|
|
|
|
|
|
|
|
|
|
25.08.26 - 15:06
|
WuXi Biologics posts 4.3% rise in first-half profit, defying biotech headwinds (SCMP)
|
|
|
WuXi Biologics, one of China's largest contract drug developers, posted a 4.3 per cent increase in profit attributable to shareholders in the first half of the year, as stronger demand and improved capacity utilisation lifted revenue and margins.
The Wuxi, Jiangsu-based company's net profit attributable to shareholders rose to 2.44 billion yuan (US$363 million) in the six months ended June, according to its filing to the Hong Kong stock exchange on Tuesday. Revenue increased 18.4 per cent to......
|
|
|
|
|
|
|
|
|
|
|
|
|
25.08.26 - 07:00
|
As global drug giants grow cautious, can Chinese biotech keep cashing in on out-licensing? (SCMP)
|
|
|
Record-breaking cross-border deals helped make some formerly loss-making Chinese biotech companies profitable in the first half of the year, but multinational drugmakers are now signalling plans to tighten deal budgets.
Analysts said deals with global partners had overtaken initial public offerings and pre-IPO fundraising as the main funding option for cash-starved Chinese biotech firms wanting to advance the discovery, clinical development and regulatory approval of new drugs. Yet questions......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
